Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus

Stroke

Volumn 38, Issue 2, 2007, Pages 281-285

  Mikdashi, Jamal ^a   Handwerger, Barry ^a   Langenberg, Patricia ^a   Miller, Michael ^a   Kittner, Steven ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

Ischemic stroke; Neurological disability; Risk factors; Systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 33846621547     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000254476.05620.14     Document Type: Article

References (28)

1. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus: patients characteristics associated with poorer outcomes. Arthritis Rheum. 1995;38:274.
2. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Paniritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337.
3. Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford). 2004;43:924-929.
4. Futrell N, Millikan C. Frequency, etiology and prevention of stroke in patients with systemic lupus erythematosus. Stroke. 1989;20:583-591.
5. Mitsias P, Levine SR. Large cerebral vessel occlusive disease in systemic lupus erythematosus. Neurology. 1994;44:385-393.
6. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117:997-1002.
7. Koskenmies S, Vaarala O, Widen E, Kere J, Palosuo T, Julkunen H. The association of antibodies to cardiolipin, beta 2-glycoprotein I, prothrombin, and oxidized low-density lipoprotein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus. Scand J Rheumatol. 2004;33:246-252.
8. Gatenby PA. Controversies in the antiphospholipid syndrome and stroke. Thromb Res. 2004;114:483-488.
9. Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke. 2000;31:1289-1293.
10. Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL Jr. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol. 2005;95:1441-1447.
11. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol. 1988;23:380-384.
12. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43:1801-1808.
13. ACR. Ad Hoc committee on neuropsychiatric lupus nomenclature and case definitions for neuropsychiatric syndromes in systemic lupus erythematosus. Arthritis Rheum. 1999;42:599-608.
14. Adams HP Jr, Bendixen BH, Kappelle LJ, Chang KC, Davis PH, Woolson RF, Clarke WR, Hansen MD. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST Trial of Org 10172 in Acute Stroke Treatment Stroke. 1993;24:35-41.
15. Goldstein L, Samsa G. Reliability of the National Institutes of Health Stroke Scale. Extension to non-neurologists in the context of a clinical trial. Stroke. 1997;28:307-310.
16. Hochberg MC. Updating the Am College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
17. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford). 2004;43:1555-1560.
18. Harris EN, Pierangeli SS. Revisiting the Anticardiolipin test and its standardization. Lupus. 2002;11:269-275.
19. Kasner SE, Chalela JA, Luciano JM, Cucchiara BL, Raps EC, McGravey ML, Conroy MB, Localia AR. Reliability and validity of estimating the NIH stroke scale score from medical records. Stroke. 1999;30:1534-1537.
20. Nightingale A, Farmer R. Ischemic stroke in young women: A nested case-control study using the UK general practice research database. Stroke. 2004;35:1574-1578.
21. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Pratt JE, Tracy RP, Kuller LH, Manzi S. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum. 2004;50:151-159.
22. Toloza SM, Uribe AG, McGwin G Jr, Alarcon GS, Fessler BJ, Bastian HM, Vila LM, Wu R, Shoenfeld Y, Roseman JM, Reveille JD. LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII Baseline predictors of vascular events. Arthritis Rheum. 2004;50:3947-3957.
23. Tirschwell D, Smith N, Heckbert S, Lemaitre R, Longstreth W, Psaty B. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology. 2004;63:1868-1875.
24. Hutter C, Austin M, Humphries S. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. Am J Epidemiol. 2004;160:430-435.
25. El-Magadmi M, Bodill H, Ahmad Y, Durrington PM, Mackness M, Walker M, Bernstein RM, Bruce IN. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation. 2004;110:399-404.
26. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology. 1997;48:891-895.
27. Krause I, Lev S, Fraser A, Blank M, Lorber M, Stojanovich L, Rovensky J, Chapman J, Sheonfeld Y. Close Association between valvular heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005.
28. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, Murphy A, Lu Y, Costigan TM, Rhine C, Levin B, Triplett DA, Mohr JP. APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;24:576-584.